Anilino liver X-receptor modulators

1. A compound of Formula I:

wherein:

b is 0-3;

R 1 is hydrogen, acyl, or optionally substituted alkyl, heterocyclo, or aralkyl;

R 2 and R 3 are independently hydrogen or optionally substituted alkyl, aryl, heteroaryl, aminoalkyl, hydroxyalkyl, or thioalkyl; one of R 2 and R 3 , or R 2 and R 3 together with the atom to which they are attached may form a carbocyclic or heterocyclic ring;

R 4 is hydrogen or together with R 1 and the atoms to which they are attached form a heterocyclic ring;

Z is —CO 2 Z 1 , —CH 2 NZ 1 Z 2 , —C(O)Z 1 , —CH(OH)Z 1 , —CH 2 OZ 1 , —CH 2 OC(O)Z 1 , or —C(O)NZ 1 Z 2 , and

Z 1 and Z 2 are independently hydrogen or optionally substituted alkyl, heterocyclo, or aralkyl;

provided, however, when R 1 is hydrogen and one of R 2 and R 3 is hydrogen, the other of R 2 and R 3 is not hydrogen or methyl.

2. The compound of claim 1 wherein R 1 is a substituted or unsubstituted benzyl group.

3. The compound of claim 1 wherein R 1 is a substituted or unsubstituted benzoyl group.

4. The compound of claim 1 wherein Z is —CO 2 H.

5. The compound of claim 1 wherein Z is —C(O)NZ 1 Z 2 and Z 1 and Z 2 are as defined in claim 1 .

6. The compound of of claim 1 wherein Z is —CO 2 Z 1 and Z 1 is as defined in claim 1 .

7. The compound of claim 1 wherein Z is —CH(OH)Z 1 and Z 1 is as defined in claim 1 .

8. A compound selected from compounds of the group consisting of

Ethyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}alaninate;

Ethyl 2-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}alaninate;

Ethyl N-(2,2,2-trifluoroethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-ethyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}glycinate;

Ethyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}glycinate;

Methyl phenyl({4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}amino)acetate hydrochloride;

Methyl N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-phenylalaninate;

Methyl (4-chlorophenyl)({4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}amino)acetate;

Methyl (3,4-dichlorophenyl)({4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}amino)acetate;

Ethyl 3-({4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)-butanoate;

Ethyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}-beta-alaninate;

Ethyl N-(4-chlorobenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]-phenyl}glycinate;

Ethyl N-(3,4-dichlorobenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(4-methylbenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}glycinate;

Ethyl N-benzyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}glycinate;

N-Methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-glycine;

1,1,1,3,3,3-Hexafluoro-2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-propan-2-ol;

2-(Methyl-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-amino)propan-1-ol;

N-1-Benzyl-N-2-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}alaninamide;

N-1-Benzyl-N-2-methyl-N-2-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}glycinamide;

N-1-Benzyl-N-3-methyl-N-3-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}-beta-alaninamide;

N-1-Methoxy-N-1-N-2-dimethyl-N-2-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoro-methyl)ethyl]phenyl}glycinamide;

1-(Methyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-amino)pentan-2-one;

1-(Methyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-amino)pentan-2-ol;

4-Chlorobenzyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]phenyl}glycinate;

2-Ethoxyethyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]-phenyl}glycinate;

2-Methoxyethyl N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)-ethyl]-phenyl}glycinate;

N 2 -Methyl-N 1 ,N 1 -bis[4-(N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycyl)morpholin-3-yl]-N 2 -{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinamide;

N 2 -Methyl-N 1 ,N 1 -bis[1-(N-methyl-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycyl)pyrrolidin-2-yl]-N 2 -{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinamide;

Ethyl N-(2,4-dichlorobenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(3-chlorobenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(4-ethoxybenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(4-methoxybenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

1-(Benzyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)-pentan-2-ol;

1-((2,2,2-Trifluoroethyl){4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)pentan-2-ol;

Ethyl N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}-N-[4-(trifluoromethyl)benzyl]glycinate;

Ethyl N-(pyridin-3-ylmethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(2-chlorobenzyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

Ethyl N-(2-methoxyethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}glycinate;

2-{4-[(2-Ethoxyethyl)(methyl)amino]phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol;

2-(Methyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)ethyl propionate;

Methyl (4-methylphenyl)({4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}amino)acetate.

9. A method for treating conditions regulated by the liver X-receptor in a mammal in need of such treatment comprising administering an effective liver X-receptor modulating amount of a compound according to claim 1 .

10. A method according to claim 9 wherein the condition treated is atherosclerosis.

11. A method according to claim 9 wherein the condition treated is dyslipidemia.

12. A method according to claim 9 wherein the condition treated is diabetes.

13. A method according to claim 9 wherein the condition treated is Alzheimers disease.

14. A method according to claim 9 wherein the condition treated is Niemann-Pick disease.